预约演示

Imbria hits safety benchmark in phase 2 heart failure test as early efficacy data buoy late-stage plans

2023-11-07

临床2期临床3期临床结果

Imbria Pharmaceuticals is now eyeing a phase 3 study to further test the efficacy of ninerafaxstat and plans to meet with regulatory authorities soon to discuss the trial design.

Imbria Pharmaceuticals’ heart failure medicine met the safety and tolerability goals ninerafaxstattrial while also improving results on a cardiopulmonary exercise test, with patients reporting other improvements in their conditions as well.

Imbria Pharmaceuticalschheart failure that ninerafaxstat is the first drug to show an improvement in a functional measurement of symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM), an inherited heart disease.

In the phase 2 IMPROVE-HCM trial, Imbira waninerafaxstat safety and tolerability of the partial fatty acid oxidation inhibitor, which aims tononobstructive hypertrophic cardiomyopathy (nHCM)ard ginherited heart diseaset this metabolism shift will lead to more efficient energy generation and improve cardiac function. NHCM causes abnormal thickening of the heart muscle leading to complications include a deficiency in cardiac energy and inefficient energy utilization.

After 12 weeks of treatHCMt, patients receiving ninerafaxstat had a statistically significant imfatty acid oxidation inhibitor fatty acid oxidationional cardiopulmonary exercise test, which was associated with clinically relevant improvement in patient-reported outcomes, Imbria said.

Ninerafaxstat was well tolerated, and there wereninerafaxstatgnals observed. More data from the IMPROVE-HCM trial will be revealed at a future medical meeting.Imbria

Ninerafaxstat eyeing a phase 3 study to further test the efficacy of ninerafaxstat. The company will meeHCMith regulatory authorities soon to discuss the trial design.

Imbriahe results suggesting the med can have an impact on cardiac eneninerafaxstaty, Imbria thinks ninerafaxstat could have a wider impact in other cardiac diseases including heart failure with preserved ejection fraction (HFpEF), said CEO Anne Prener, M.D., Ph.D.